Peninsula biotech scores $80M upfront in potential $1.6 billion cancer drug deal

The South San Francisco company's technology is designed to mask a drug until it lands on a cancer cell, where it then is unmasked and spills out its payload to destroy the cell with minimal damage to surrounding healthy tissue.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.